

We stress that it is important to view the possible hazard of aflatoxin from the perspective of the many everyday possible hazards of life and with the knowledge that there are a great many uncertainties in the use of animal bioassay data in extrapolation to humans. As we discussed at length, the promotional aspects of cancer are also critical, and it is likely that the hazard from aflatoxin will be much lower in the absence of some toxicity in the liver such as from hepatitis virus, alcoholic cirrhosis, or the maximum tolerated dose in rodents. Since the HERP values for synthetic pollutants, including pesticides, are usually an order of magnitude less than that from aflatoxin, concern over them should be even less.

BRUCE N. AMES

RENAE MAGAW

Department of Biochemistry,  
University of California,  
Berkeley, CA 94720

LOIS SWIRSKY GOLD

Lawrence Berkeley Laboratory,  
Berkeley, CA 94720

#### REFERENCES

1. H. Autrup, T. Seremet, J. Wakhisi, A. Wasunna, *Cancer Res.* 47, 3430 (1987); S. V. Thomson *et al.*, *J. Appl. Environ. Microbiol.* 35, 1150 (1978); S. J. Cheng *et al.*, *Carcinogenesis* 6, 903 (1985).

**Response:** We generally agree both with Stoloff's letter and the response of Ames *et al.* However, we were aware that the reliability of the connection between human cancers and exposure to aflatoxin B1 has been called into question by the realization that a more important risk factor is infection with hepatitis B virus, which inevitably confounds the data. Nonetheless, we believe that the certainty for human carcinogenesis is high, although not absolute; it is certainly superior to the evidence for cancers caused by dioxin. The 20 parts-per-billion action level for aflatoxin in peanut butter may indeed have been set at a detection limit (although we do not like this practice). However, as Stoloff himself points out, it has *not* been reduced, although a modest, in our view inadequate, proposal to reduce it to 15 ppb was made in 1977 long after more sensitive detection equipment was available. The proposal was abandoned.

RICHARD WILSON

E. A. C. CROUCH

Department of Physics and Energy and  
Environmental Policy Center,  
Harvard University,  
Cambridge, MA 02138

**Erratum:** In table 1 of the article "Changes in the distribution of American family incomes, 1947 to 1984" by Frank Levy (22 May, p. 923), the first quintile (%) for 1949 was inadvertently omitted. It should have been 4.5.


## New! Micro-g® Table Top Vibration Isolators

- High-performance portable, low-profile isolator platform for small instruments
- Superior attenuation efficiency both horizontally and vertically
- Granite or stainless steel tops in several standard sizes—plus custom configurations
- Gimbal Piston® isolator units can be used with 2" thick optical breadboards

Granite tops are avail-

able in two sizes: 24" square and 24" x 30", with three or four isolator units. Stainless tops are available in three sizes: 24 3/4" x 35", 29 3/4" square, and 29 3/4" x 35", with four isolators.

See how this exclusive TMC innovation can advance the precision and efficiency of your work—with unparalleled economy. Write or call today for new PRODUCT BULLETIN and price list.



Technical Manufacturing Corporation

15 Centennial Drive • Peabody, MA 01960, USA • Telephone: 617-532-6330 • Telex: 951408

Circle No. 112 on Readers' Service Card

TMC-26

## INTRODUCING THE JOURNAL OF LIPOSOME RESEARCH

### Call for Papers

The Journal of Liposome Research is a new publication by Marcel Dekker, Inc. whose mission is to present high quality original liposome research and a small number of selected reviews. The subjects will be broad, ranging from biophysical analysis of liposome membranes to clinical applications of liposome-encapsulated drugs. Only papers focused on some aspect of liposome research will be considered. Dr. Marc J. Ostro, Vice Chairman and Chief Science Officer of The Liposome Company, Inc. will be the editor-in-chief and to whom all manuscripts should be submitted. The Journal has attracted an outstanding international editorial board detailed below. It is anticipated that the first issue will be published in the Summer of 1987 and will initially appear quarterly.

#### EDITOR-IN-CHIEF

Marc J. Ostro, Ph.D.  
Vice Chairman and Chief Science Officer  
The Liposome Company, Inc.  
One Research Way  
Princeton, New Jersey 08540

#### EDITORIAL BOARD

Dr. Carl R. Alving Walter Reed Army Institute of Research	Dr. Enrico Mihich Roswell Park Memorial Institute
Dr. John D. Baldeschwieler California Institute of Technology	Dr. Richard E. Pagano Carnegie Institute
Dr. Yechezkel Barenholz Hadassah Medical School	Dr. Demetrios Papahadjopoulos University of California, San Francisco
Dr. Gerald P. Bodey M.D. Anderson Hospital & Tumor Institute	Dr. Bengt Samuelsson Karolinska Institute
Dr. Denis J. Chapman University of London	Dr. Alan C. Sartorelli Yale School of Medicine
Dr. Pieter R. Cullis University of British Columbia	Dr. Tsugio Shimamoto Takeda Chemical Industries, Ltd., Japan
Dr. Gregory Gregoriadis The Royal Free Hospital	Dr. Junzo Sunamoto University of Nagasaki, Japan
Dr. Sol M. Gruner Princeton University	Dr. Frank Szoka University of California, San Francisco
Dr. Leaf Huang University of Tennessee	Dr. Andre Trouet IRE-Celltag
Dr. Keizo Inoue University of Tokyo, Japan	Dr. Moseley Waite The Bowman Gray School of Medicine
Dr. Maurice Kates University of Ottawa	Dr. John N. Weinstein National Institute of Health
Dr. Gabriel Lopez-Berestein M.D. Anderson Hospital & Tumor Institute	Dr. Gerald Weissman N.Y.U. Medical Center

Circle No. 151 on Readers' Service Card